Minute Insight: Current Testing Technologies Can Detect The Omicron Variant
Executive Summary
As fears about vaccine escape grow, test manufacturers have been quick to assert that their tests can spot the new Omicron variant of SARS-CoV-2
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.